153 related articles for article (PubMed ID: 23096214)
1. Liver lesion characterization: the wrong choice of contrast agent can mislead the diagnosis of hemangioma.
Pradella S; Lucarini S; Colagrande S
AJR Am J Roentgenol; 2012 Nov; 199(5):W662. PubMed ID: 23096214
[No Abstract] [Full Text] [Related]
2. Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight.
Pastor CM
Radiology; 2010 Nov; 257(2):589. PubMed ID: 20959554
[No Abstract] [Full Text] [Related]
3. Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast.
Hylton NM
AJR Am J Roentgenol; 2003 Sep; 181(3):677-8. PubMed ID: 12933458
[No Abstract] [Full Text] [Related]
4. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
5. [Hepatocyte targeted MR contrast agent--Gd-BOPTA(E-7155)].
Kuwatsuru R; Katayama H
Nihon Rinsho; 2001 Oct; 59 Suppl 6():323-7. PubMed ID: 11761966
[No Abstract] [Full Text] [Related]
6. Hepatocyte-specific magnetic resonance imaging contrast agents.
Fidler J; Hough D
Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
[No Abstract] [Full Text] [Related]
7. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.
Fowler KJ; Brown JJ; Narra VR
Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400
[TBL] [Abstract][Full Text] [Related]
8. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
[TBL] [Abstract][Full Text] [Related]
9. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
10. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
11. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
12. Optimization of single injection liver arterial phase gadolinium enhanced MRI using bolus track real-time imaging.
Sharma P; Kalb B; Kitajima HD; Salman KN; Burrow B; Ray GL; Martin DR
J Magn Reson Imaging; 2011 Jan; 33(1):110-8. PubMed ID: 21182128
[TBL] [Abstract][Full Text] [Related]
13. Effect of gadolinium chelate contrast agents on diffusion weighted MR imaging of the liver, spleen, pancreas and kidney at 3 T.
Wang CL; Chea YW; Boll DT; Samei E; Neville AM; Dale BM; Merkle EM
Eur J Radiol; 2011 Nov; 80(2):e1-7. PubMed ID: 20646887
[TBL] [Abstract][Full Text] [Related]
14. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
[TBL] [Abstract][Full Text] [Related]
15. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media.
Marin D; Brancatelli G; Federle MP; Lagalla R; Catalano C; Passariello R; Midiri M; Vilgrain V
Clin Radiol; 2008 May; 63(5):577-85. PubMed ID: 18374723
[TBL] [Abstract][Full Text] [Related]
16. Low-dose gadobenate dimeglumine-enhanced MRI in the detection and characterization of focal liver lesions.
Kirchin MA; Spinazzi A
Acad Radiol; 2002 May; 9 Suppl 1():S121-6. PubMed ID: 12019846
[No Abstract] [Full Text] [Related]
17. [Multiple cavernous hemangioma progressing in size in a cirrhotic liver].
Henninger B; Bale R; Schocke M
Rofo; 2010 Apr; 182(4):357-9. PubMed ID: 19953432
[No Abstract] [Full Text] [Related]
18. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
20. MRI findings of hepatocellular carcinoma.
Wiwanitkit V
Magn Reson Imaging; 2011 Feb; 29(2):303. PubMed ID: 21129874
[No Abstract] [Full Text] [Related]
[Next] [New Search]
